Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2 Antony PA; Restifo NPJ Immunother 2005[Mar]; 28 (2): 120-8CD4+CD25+ T regulatory (Treg) cells control immunologic tolerance to self-antigens and play a role in suppressing antitumor immune responses, but the mechanism of suppression in vivo remains uncertain. Recently, signaling through the high-affinity interleukin-2 (IL-2) receptor has been shown to be critical for Treg cell differentiation and survival in vivo. Mice deficient in IL-2 or its receptor (CD25 or CD122) or deficient in downstream signaling molecules, including JAK-3 and STAT-5, do not develop a stable population of Treg cells and subsequently acquire lymphoproliferative disease and autoimmunity. in vitro, IL-2 is required to expand Treg cells and to induce their suppressive characteristics. Conversely, IL-2-based regimens can activate cellular antitumor immunity and are the mainstay of immunotherapies directed against melanoma and kidney cancers. Given the seemingly disparate effects of IL-2, the authors discuss the possibility that IL-2 may not be the optimal T-cell growth factor in vivo, but rather an inducer of self-tolerance. The authors propose that other gamma c-signaling cytokines, including IL-15, may be alternative choices for the immunotherapy of cancer.|Adoptive Transfer[MESH]|Animals[MESH]|Binding Sites[MESH]|Bone Marrow Cells/metabolism[MESH]|CD4-Positive T-Lymphocytes/cytology/*immunology[MESH]|Dendritic Cells/cytology[MESH]|Humans[MESH]|Immunotherapy/*methods[MESH]|Interleukin-2/metabolism/*physiology[MESH]|Lymphoproliferative Disorders/therapy[MESH]|Mice[MESH]|Mice, Transgenic[MESH]|Models, Biological[MESH]|Neoplasms/metabolism/*therapy[MESH]|Phenotype[MESH]|Receptors, Interleukin-2/*biosynthesis[MESH]|T-Lymphocytes/metabolism[MESH] |
